期刊文献+

顺铂和氟尿嘧啶增强食管癌细胞NKG2D配体的表达及CIK细胞的杀伤活性 被引量:2

Cisplatin and 5-fluorouracil Enhance Expression of NKG2D Ligands and CIK Cells Killing Effect of Human Esophagus Carcinoma Cell EC9706
下载PDF
导出
摘要 目的研究顺铂(Cisplatin,DDP)和氟尿嘧啶(5-fluorouracil,5-Fu)对人食管癌EC9706细胞NKG2D配体表达及CIK细胞杀伤活性的影响。方法 MTT法测定DDP、5-Fu的50%抑制浓度(IC50);以1/2 IC50浓度DDP、5-Fu作用EC9706细胞72 h,RT-PCR检测DNA损伤修复系统相关信号分子的表达。流式细胞仪检测DDP、5-Fu作用前、后EC9706细胞NKG2D配体的表达。乳酸脱氢酶释放法检测效靶比20∶1时,CIK细胞对DDP、5-Fu作用前、后EC9706细胞的杀伤活性。结果 DDP、5-Fu的IC50分别为5μg/ml、10μg/ml。DDP、5-Fu可上调DNA损伤修复系统相关信号分子mRNA的表达。DDP与EC9706细胞共孵育72 h后,EC9706细胞MICA、MICB、ULBP2、ULBP3表达较DDP作用前明显增强(P<0.05),ULBP1无明显变化(P>0.05)。5-Fu与EC9706细胞共孵育72 h后,EC9706细胞MICA、ULBP2、ULBP3表达明显增强(P<0.05),MICB、ULBP1无明显变化(P>0.05)。效靶比20∶1时,CIK细胞对EC9706细胞的杀伤活性为(37.08±0.62)%,CIK细胞对1/2 IC50DDP、1/2 IC505-Fu作用后的EC9706细胞杀伤活性分别为(59.33±2.10)%、(52.44±0.97)%,与作用前相比差异均有统计学意义(P<0.05)。结论 DDP、5-Fu通过激活DNA损伤修复系统相关信号分子,提高EC9706细胞NKG2D配体的表达,从而增强EC9706细胞对CIK细胞杀伤的敏感度。 Objective To explore the effects of Cisplatin(DDP) and 5-fluorouracil(5-Fu) on the expression of NKG2D ligands of human esophagus carcinoma cell EC9706 and cytokine-induced killer(CIK) cells cytotoxicity.Methods The IC50 of DDP,5-Fu against EC9706 cells were measured by MTT assay.Expressions of signal pathway molecules involved in DNA damage and repair system were detected by RT-PCR.The expression of NKG2D ligands(MICA,MICB,ULBP1,ULBP2,ULBP3) were analyzed by flow cytometery.Cytotoxicities of CIK cells against EC9706 cells before and after cultured by 1/2 IC50 DDP or 5-Fu were analyzed by LDH releasing assay at effector-to-target cell ratio(E∶T) of 20∶1.Results DDP,5-Fu could decrease the proliferation and survival rate of EC9706 cells,the IC50 was 5 μg/ml and 10 μg/ml,respectively,which increased mRNA expressions of signal pathway molecules involved in DNA damage and repair system.MICA,MICB,ULBP2,ULBP3 on EC9706 cells were over expressed after 72 h cultured with 1/2 IC50 DDP,while expression of MICA,ULBP2,ULBP3 were higher after treated by 1/2 IC50 5-Fu.Cytotoxicity of CIK cells against EC9706 cells cultured by 1/2 IC50 DDP,1/2 IC50 5-Fu were(37.08±0.62)%,(59.33±2.10)%,(52.44±0.97)%,respectively.Cytotoxicity of CIK cells against EC9706 cells cultured by either 1/2 IC50 DDP or 1/2 IC50 5-Fu was significantly enhanced.ConclusionThe results indicate that DDP or 5-Fu can enhance the susceptibility of EC9706 cells to CIK cells-mediated killing effect by upregulating the expressions of NKG2D ligands through activating signal pathway molecules involved in DNA damage and repair system.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2012年第7期765-768,共4页 Cancer Research on Prevention and Treatment
基金 河南省科技计划攻关基金资助项目(112102310126)
关键词 食管癌 顺铂 氟尿嘧啶 细胞因子诱导的杀伤细胞 NKG2D Esophagus carcinoma Cisplatin Fluorouracil CIK cells NKG2D
  • 相关文献

参考文献4

二级参考文献45

  • 1梅家转,郭坤元,魏红,梅常红.不同肿瘤细胞表面MICA的表达及NK细胞杀伤活性的研究[J].中国免疫学杂志,2007,23(1):34-37. 被引量:16
  • 2梅家转,郭坤元,魏红梅,常红,宋朝阳.NKG2D介导NK细胞对鼻咽癌细胞杀伤作用的体外研究[J].肿瘤防治研究,2007,34(4):233-236. 被引量:9
  • 3梅家转,郭坤元,吴远彬,周健,魏红梅.NK细胞对人鼻咽癌细胞CNE2裸鼠皮下移植瘤的抑制作用[J].肿瘤防治研究,2007,34(6):425-427. 被引量:5
  • 4Rohner A, Langenkamp U, Siegler U, et al. Differentiation- promoting drugs up regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid. Leukemia cells to natural killer cell-mediated lysis[J] . Leuk Res, 2007, 31 (10): 1393-1402.
  • 5Valas Gomez M, Chisholm SE, Cassady-Cain RL, et al. Selective induction of expression of a ligand for the NKG2D re ceptor by proteasome inhibitors[J]. Cancer Res, 2008, 68(5) : 1546-1554.
  • 6Roda JM, Joshi T, Butchar JP, et al. The activation of natn ral killer cell effector functions by cetuximab coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines[J]. Clin Cancer Res, 2007, 13(21 ):6419-6428.
  • 7Chrul S, Polakowska E, Szadkowska A, et al. Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglohulin-like receptors KIR2DIA, KIR2DL2, and KIR3DL2 in natural killer cells[J]. Mediators Inflamm, 2006 (4) :469-457.
  • 8Chen XM, Xu XQ, Sun K, et al. NKG2D ligands expression and NKG2D mediated cytotoxicity in human laryngeal squa- mous carcinoma cells [J]. Scand J Immunol, 2008, 67 (5):441-447.
  • 9Frazier JL, Han JE, Lira M, Olivi A. Immunotherapy combined with chemotherapy in the treatment of tumors [ J]. Neurosurg Clin N Am, 2010, 21(1) : 187-194.
  • 10Merlo A, Turrini R, Dolcetti R, Zanovello P, Amadori A, Rosato A. Adoptive cell therapy against EBV-related malignancies: A survey of clinical results [J]. Expert Opin Biol Ther, 2008, 8 (9) : 1265-1294.

共引文献31

同被引文献25

  • 1梅家转,郭坤元,魏红,梅常红.不同肿瘤细胞表面MICA的表达及NK细胞杀伤活性的研究[J].中国免疫学杂志,2007,23(1):34-37. 被引量:16
  • 2Textor S, Fiegler N,Arnold A,et al. Human NK cells are aler ted to induction ot" p53 in cancer cells by upregulation of the NKG2Dligands ULBPI and UI.BP2[J]. Cancer Res. 2011,71 (18) : 5998-6009.
  • 3Linn YC,Yong HX,Niam M,et al. A phase [/I] clinical tria of autologous cytokine induced killer cells as adjuvant immuno therapy for acute and chronic myeloid leukemia in elinicalremis sion[J]. Cytotherapy,2012,14(7) :851-859.
  • 4Mesiano G,Todorovic M.Gammaitoni l.,et al. Cytokine-indueed killer (CIK) cells as feasible and effective adoptive immunothera py for the treatment of solid tumors[J]. Expert ()pin Biol Ther, 2012,12(6) :673-684.
  • 5Bae JH, Kim SJ, Kim MJ, et ai. Susceptibility to natural killer ceil-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16- binding protein-1 induction[J]. Cancer Sci, 2012,103 ( 1 ) : 7-16.
  • 6Roengvoraphoj M, Tsongalis G J, Dragnev K H, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer:focus on epidermal growth factor re- ceptor mutation testing and mutation-positive patients [ J ]. Cancer Treat Rev,2013,39 ( 8 ) : 839-850.
  • 7Lee C K, Brown C, Gralla R J, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival : a meta-ana/ysis[ J]. J Natl Cancer lnst,2013,105(9) :595-605.
  • 8Asami K. Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs [ J ]. Gan To Kagaku Ryoho ,2014 ,41( 5 ) :533-538.
  • 9Zhang L, Zhao G, Hou Y, et aL The experimental study on the treatment of cytokine-induced killer cells combined with EGFR monoclonal antibody against gastric cancer[ J]. Cancer Biother Ra- diopharm ,2014,29 ( 3 ) :99-107.
  • 10Ullrieh E,Koch J,Cerwenka A,et a/. New prospects on the NKG2D/ NKG2DL system for oncolegy[ J ]. Oncoimmunology ,2013 ,2 ( 10 ) : e26097.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部